IRF5 3'UTR polyadenylation

IRF5 3'UTR Polyadenylation — The Molecular Switch That Amplifies Interferon Output

At the heart of the innate immune system sits a protein called IRF5 (Interferon Regulatory Factor 5) | A master transcription factor that, when activated by viral or microbial signals, enters the cell nucleus and switches on genes for type I interferons and pro-inflammatory cytokines including TNF-α, IL-6, and IL-12. IRF5 is the key decision-maker that determines how vigorously your immune system responds to threats — but when it runs too high chronically, it becomes a driver of autoimmune disease. The rs10954213 variant, located in the 3' untranslated region of the IRF5 gene, is the best-characterized causal variant in one of genetics' most replicated autoimmune susceptibility loci. Unlike the nearby rs2004640 variant (which alters mRNA splicing) and rs2280714 (which is a tag SNP in linkage disequilibrium), rs10954213 directly controls how long the IRF5 messenger RNA survives in the cell — and therefore how much IRF5 protein gets made.

The Mechanism

The rs10954213 variant works through a process called alternative polyadenylation | A mechanism by which the same gene can produce mRNA molecules of different lengths from the same 3' end; the cell's RNA-processing machinery recognizes a signal sequence (AAUAAA) and cleaves the mRNA at that point, adding a poly-A tail that protects the mRNA from degradation. The A allele of rs10954213 creates a canonical AAUAAA polyadenylation signal approximately 100 nucleotides upstream of the default cleavage site. When this proximal signal is present, the cell's polyadenylation machinery cleaves the mRNA at that upstream position, producing a shorter 3'-UTR isoform. This shorter transcript has two important properties: it escapes microRNA-mediated degradation | MicroRNAs are small RNA molecules that bind to complementary sequences in the 3'-UTR and mark mRNA transcripts for degradation; the longer 3'-UTR contains more such binding sites, making the longer isoform less stable that would normally limit IRF5 protein levels, and it accumulates in the cytoplasm at higher concentrations.

The G allele disrupts this proximal polyadenylation signal, forcing the cell to use a more distal cleavage site. The resulting longer 3'-UTR is less stable and contains more miRNA target sites, leading to lower IRF5 protein output. The UK SLE families study | Cunninghame Graham et al., Human Molecular Genetics 2007; 380 SLE nuclear families from the United Kingdom identified rs10954213 as the functional element with the strongest correlation to IRF5 mRNA expression levels (P=1×10⁻¹⁴). Consistent with its role as a proximate causal variant, rs10954213-A is in tight linkage disequilibrium with rs2280714-T (r²=0.79, D'=1.0), meaning that population studies using rs2280714 as a tag SNP are effectively measuring the same functional signal.

The Evidence

The most direct functional evidence comes from lymphoblastoid cell line studies across three ancestral populations. The Rullo et al. study | Ann Rheum Dis 2010; lymphoblastoid cells from CEU (European), CHB+JPT (East Asian), and YRI (Yoruba Nigerian) populations from the HapMap project showed that IRF5 mRNA levels were consistently elevated in A-allele carriers compared to G/G homozygotes, with approximately 1.7-fold higher expression in Europeans — a pattern that held across all three ancestral groups tested. Critically, this elevated mRNA translated to elevated production of type I interferons (IFN-α) and IFN-inducible chemokines, directly linking the mRNA stability effect to downstream immune output.

For systemic lupus erythematosus (SLE), the rs10954213-A allele is part of the TAT risk haplotype (rs2004640-T / rs10954213-A / rs2280714-T) that has been replicated across more than 28 studies. A meta-analysis of these studies | Systemic review: 11,228 SLE cases and 14,374 controls; Bentham et al. Nature Genetics 2019 found overall OR=1.39 for the T allele at rs2004640 (the haplotype tag), with the combined haplotype signal reaching P=2.11×10⁻¹⁶ when the Korean replication data are pooled across ancestries. The A allele's contribution is functional: Niewold et al. | Ann Rheum Dis 2012; 200+ SLE patients and controls showed that IRF5 haplotypes carrying rs10954213-A explained over 70% of genetic risk for elevated serum IFN-α, and were specifically linked to production of anti-dsDNA and anti-Ro autoantibodies — the hallmark autoantibodies that drive kidney and skin disease in lupus.

Beyond SLE, the rs10954213-A haplotype is associated with systemic sclerosis (scleroderma). A Japanese cohort study | Furukawa et al. 2010; 283 SSc cases, 279 controls found that the IRF5 3' haplotype showed an OR of 1.42 (95% CI 1.15–1.75, P=0.0012), with preferential enrichment in the most severe disease subtypes — diffuse cutaneous SSc and anti-topoisomerase I antibody-positive disease. This indicates that higher IRF5 expression drives not only susceptibility but also disease severity and phenotype in scleroderma.

Practical Implications

For individuals carrying one or two copies of the A allele, the practical implication is that your innate immune system has a modestly elevated baseline interferon output and a lower threshold for sustaining interferon responses. This does not mean autoimmune disease is inevitable — most A allele carriers remain healthy — but it means earlier recognition and evaluation of symptoms is more important than it would be for GG individuals. The autoimmune conditions most closely linked to this variant are SLE, systemic sclerosis, and Sjögren syndrome. Early diagnosis of these conditions is critical: treatment initiated before significant organ damage dramatically improves long-term outcomes for all three conditions.

For AA homozygotes, the risk picture is more significant. Both chromosomes produce the shorter, high-stability IRF5 mRNA isoform. In the context of concurrent rs2004640-T and rs4728142 indel risk alleles (the full TAT haplotype), the combined effect on IRF5 expression can be substantial, and proactive monitoring with a rheumatologist becomes more medically justified. Serum IFN-α levels in TAT-homozygous SLE patients can be up to 7.6-fold above those seen in protective-genotype individuals, a molecular signature that is measurable and tracked in specialty centers.

Interactions

The rs10954213 variant sits within the broader IRF5 haplotype architecture alongside two other functional elements: rs2004640 (splice site variant enabling alternative exon 1B, increasing IRF5 isoform diversity) and rs4728142 (promoter CGGGG indel that increases SP1 transcription factor binding and IRF5 baseline transcription). Together these three elements drive IRF5 dysregulation at three levels — transcription, splicing, and mRNA stability — and individuals carrying all three risk alleles show the highest IRF5 output and autoimmune risk.

Additionally, IRF5 interacts additively with STAT4 (rs7574865), which sits downstream of IRF5 in the interferon signaling cascade. While IRF5 controls interferon production, STAT4 controls how sensitively immune cells respond to those interferons. Individuals with risk alleles at both loci can reach substantially amplified autoimmune risk — up to OR=6.78 with five combined IRF5+STAT4 risk alleles in Sjögren syndrome — reflecting a feed-forward amplification loop in interferon signaling.